Abstract
Human breast carcinoma is biologically heterogeneous, and its clinical course may vary from one which is indolent to one which rapidly progresses. Although it is the metastasis rather than the primary tumor that ultimately overwhelms the patients, studies concerning the DNA pattern have focused on the primary tumors. This study was undertaken to identify heterogeneities between primary tumors and metastases, and to evaluate the prognostic significance of the ploidy pattern and the S-phase fraction (SPF) of metastatic nodes in axillary node positive patients. Seventy-four frozen specimens of the primary and corresponding metastatic nodes from 37 patients have been analyzed by flow cytometry and the SPF calculated. The results of ploidy pattern analysis in primaries revealed 25 diploidy (67.6%) and 12 aneuploidy (32.4%), while those in metastasis showed 17 diploidy (46.0%) and 20 aneuploidy (54.0%). The aneuploidy group in metastatic nodes had the poorer histological grade (85.0% vs. 15.0%, p = 0.02), and more mean metastatic nodes (5.75 ± 2.10 vs. 3.05 ± 1.56, p = 0.018), and more frequent lymphatic vessel invasion (65.0% vs. 11.8%, p = 0.031) than its counterpart. Decreased expression of ER (70.6% vs. 25.0% p = 0.006) and increased expression of c-erbB2 (65.0% vs. 23.5%, p = 0.012) were observed in the aneuploidy of metastatic nodes. The group with higher SPF in metastatic nodes had more metastatic nodes (5.47 ± 2.31 vs. 4.00 ± 1.78, p = 0.042), and the higher incidence of lymphatic vessel invasion (57.9% vs. 22.2%, p = 0.027), and poor histological grade (71.4% vs. 37.5%, p = 0.039). In conclusion, the cell populations in metastatic nodes revealed DNA pattern which differed from that of primary tumors. The ploidy pattern and SPF in metastatic nodes might be considered as discriminate measure for risk factors in breast cancer patients with positive axillary node.
Similar content being viewed by others
References
Fidler IJ: Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 50(19): 6130-6138, 1990
Fidler IJ: Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res 38(9): 2651-2660, 1978
Nicolson GL: Generation of phenotypic diversity and progression in metastatic tumor cells. Cancer Metast Rev 3: 25-42, 1984
Heppner GH: Tumor heterogeneity. Cancer Res 44: 2259-2265, 1984
Fidler IJ, Poste G: The cellular heterogeneity of malignant neoplasms: implications for adjuvant chemotherapy. Semin Oncol 12: 207-221, 1985
Price JE: The biology of metastatic breast cancer. Cancer 66(6 Suppl): 1313-1320, 1990
Fisher ER, Anderson S, Redmond C, Fisher B: Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. 10-year pathologic and clinical prognostic discriminants. Cancer 71: 2507-2514, 1993
Vindeløv LL, Christensen IJ, Nissen NI: A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3: 323-327, 1983
Vindeløv LL, Christensen IJ, Nissen NI: Standardization of high-resolution flow cytometric DNA analysis by the simultaneous use of chicken and trout red blood cells as internal reference standards. Cytometry 3: 328-331, 1983
Bonsing BA, Beerman H, Kuipers-Dijkshoorn N, Fleuren GJ, Cornelisse CJ: High levels of DNA index heterogeneity in advanced breast carcinomas. Evidence for DNA ploidy differences between lymphatic and hematogenous metastases. Cancer 71: 382-391, 1993
Vindeløv LL, Christensen IJ, Jensen G, Nissen NI: Limits of detection of nuclear DNA abnormalities by flow cytometric DNA analysis. Results obtained by a set of methods for sample-storage, staining and internal standardization. Cytometry 3: 332-339, 1983
Fisher B, Gunduz N, Costantino J, Fisher ER, Redmond C, Mamounas EP, Siderits R: DNA flow cytometric analysis of primary operable breast cancer. Relation of ploidy and S-phase fraction to outcome of patients in NSABP B-04. Cancer 68: 1465-1475, 1991
Gerdes J, Becker MH, Key G, Cattoretti G: Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J Pathol 168: 85-86, 1992
Han S, Yun IJ, Noh DY, Choe KJ, Song SY, Chi JG: Abnormal expression of four novel molecular markers represents a highly aggressive phenotype in breast cancer. Immunohistochemical assay of p53, nm23, erbB-2, and cathepsin D protein. J Surg Oncol 65: 22-27, 1997
Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: and imbalance of positive and negative regulation. Cell 64: 313-321, 1992
Baildam AD, Zaloudik J, Howell A, Barnes DM, Turnbull L, Swindell R, Moore M, Sellwood RA: DNA analysis by flow cytometry, response to endocrine treatment and prognosis in advanced carcinoma of the breast. Br J Cancer 55: 553-559, 1987
Dressler LG, Seamer LC, Owens MA, Clark GM, McGuire WL: DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 61: 420-427, 1988
Hitchcock A, Ellis IO, Robertson JF, Gilmour A, Bell J, Elston CW, Blamey RW: An observation of DNA ploidy, histological grade, and immunoreactivity for tumour-related antigens in primary and metastatic breast carcinoma. J Pathol 159: 129-134, 1989
Blanco G, Holli K, Heikkinen M, Kallioniemi OP, Taskinen P: Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading. Br J Cancer 62: 142-146, 1990
Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T, McGuireWL: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320: 627-633, 1989
Beerman H, Smit VT, Kluin PM, Bonsing BA, Hermans J, Cornelisse CJ: Flow cytometric analysis of DNA stemline heterogeneity in primary and metastatic breast cancer. Cytometry 12: 147-154, 1991
Meyer JS, Wittliff JL: Regional heterogeneity in breast carcinoma: thymidine labeling index, steroid hormone receptors, DNA ploidy. Int J Cancer 47: 213-220, 1991
Beerman H, Bonsing BA, van de Vijver MJ, Hermans J, Kluin PM, Caspers RJ, van de Velde CJ, Cornelisse CJ: DNA ploidy of primary breast cancer and local recurrence after breast-conserving therapy. Br J Cancer 64: 139-143, 1991
Hedley DW, Clark GM, Cornelisse CJ, Killander D, Kute T, Merkel D: Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Report of the DNA Cytometry Consensus Conference. Cytometry 14: 482-485, 1993
Clayton F, Hopkins CL: Pathologic correlates of prognosis in lymph node-positive breast carcinomas. Cancer 71: 1780-1790, 1993
Lee AK, DeLellis RA, Silverman ML, Heatley GJ, Wolfe HJ: Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J Clin Oncol 8: 1457-1465, 1990
Bettelheim R, Penman HG, Thornton-Jones H, Neville AM: Prognostic significance of peritumoral vascular invasion in breast cancer. Br J Cancer 50: 771-777, 1984
Newby JC, Johnston SR, Smith IE, Dowsett M: Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 3: 1643-1651, 1997
Yu D, Liu B, Jing T, Sun D, Price JE, Singletary SE, Ibrahim N, Hortobagyi GN, Hung MC: Overexpression of both p185cerbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene 16: 2087-2094, 1998
Bitran JD, Samuels B, Trujillo Y, Klein L, Schroeder L, Martinec J: Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy. Clin Cancer Res 2: 1509-1513, 1996
Wosikowski K, Schuurhuis D, Kops GJ, Saceda M, Bates SE: Altered gene expression in drug-resistant human breast cancer cells. Clin Cancer Res 3: 2405-2414, 1997
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kang, HS., Youn, YK., Oh, SK. et al. Flow cytometric analysis of primary tumors and their corresponding metastatic nodes in breast cancer. Breast Cancer Res Treat 63, 81–87 (2000). https://doi.org/10.1023/A:1006470614782
Issue Date:
DOI: https://doi.org/10.1023/A:1006470614782